Skip to content
Companies

Hepion Pharmaceuticals

Blood tests for early liver cancer detection

Raised to date

$3.8M

of $3.8M offered across 2 Form D filings

Investors
33
Last filed
Aug 5, 2026

About

Hepion Pharmaceuticals is a New Jersey diagnostics company developing non-invasive liquid biopsy tests for the early detection and surveillance of hepatocellular carcinoma (HCC) in people living with cirrhosis. In 2026 it pivoted from liver-disease drug development to cancer diagnostics, assembling two complementary blood-based biomarker platforms: a clinically validated methylated DNA (mSEPT9) test and an in-licensed circulating tumor RNA (ctRNA) assay. The company is pursuing a staged commercialization path, launching through a CLIA laboratory before seeking FDA approval, and has identified partnership routes to accelerate market access. It trades publicly under the ticker HEPA.

Pairs a near-commercial, clinically validated methylated DNA test with a next-generation ctRNA assay aimed specifically at hepatocellular carcinoma surveillance in cirrhotic patients, a setting where current standard-of-care surveillance is reported to miss up to 75% of early-stage cancers.

Funding

$3.1M, first sold Jul 2026$3.1M soldApr 2026Jul
Now
  • EquityFiled Aug 5, 2026Form D
    $3.1M/ $3.1M
  • EquityFiled Apr 22, 2026Form D
    $700K/ $700K

Product

Methylated DNA (mSEPT9) biomarker test

Molecular diagnostic test

A blood-based liquid biopsy test that detects methylated SEPT9 DNA to identify early-stage hepatocellular carcinoma in high-risk patients with cirrhosis.

  • Blood-based, non-invasive sample collection
  • Methylated SEPT9 DNA biomarker readout
  • Clinically validated and positioned for near-term commercialization

Built for

Hepatologists, gastroenterologists, and oncology care providers managing patients with cirrhosis who require routine hepatocellular carcinoma surveillance, plus the at-risk cirrhotic patients themselves.

People on file